Skip to main content

Fiscal Wizard · Single-issue tearsheet

IBO / Jun 22, 2026 Run #7635

IBO

Impact BioMedical Inc.

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc

Composite verdict

F 9.1 / 100
Bearish setup · Reversal 7 drivers · 5 gates blocking
  • Rate of Change
  • Parabolic SAR Flip
  • Fibonacci Retracement
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 455th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 15 signals100% Bear
Momentum Bearish 7Mean-reversion Neutral 45

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

17.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Free Cash Flow Yield 0
EPS Growth (YoY) 100
FCF Margin 0
P/B 75
EBITDA Margin 0

Technicals Bearish

0.4 / 100

Bearish setup leads (Rate of Change, Parabolic SAR Flip, Fibonacci Retracement); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 4
Parabolic SAR Flip 14
MA Rejection 18

Risk Gates

5 blocking 5 caution

5 guards active, 25 signals gated.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for IBO.